53 related articles for article (PubMed ID: 31243249)
1. Fatal myasthenia gravis (MG) associated with myositis and myocarditis in a patient with pre-existing MG treated by adjuvant nivolumab for a stage III melanoma.
Emile J; Cauquil C; Carpentier D; Routier E; Robert C
Eur J Cancer; 2024 Jul; 205():114098. PubMed ID: 38761774
[No Abstract] [Full Text] [Related]
2. Statin-associated necrotizing autoimmune myopathy with concurrent myasthenia gravis.
Frasson E; Simonetto M; Bertolasi L; Caneve G; Vilotti C; Ruzza G; Perelli A; Piccinno MG; Monaco S
Clin Case Rep; 2021 May; 9(5):e03925. PubMed ID: 34026125
[TBL] [Abstract][Full Text] [Related]
3. Immune-mediated necrotizing myopathy: antibodies and forecast. A literature review.
Toledo Del Castillo B; Rodriguez Represa FJ; Arias Lotto F; Nieto González JC
An Pediatr (Engl Ed); 2024 Apr; 100(4):293-298. PubMed ID: 38599932
[No Abstract] [Full Text] [Related]
4. Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics.
Lazaridis K; Tzartos SJ
Front Immunol; 2020; 11():212. PubMed ID: 32117321
[TBL] [Abstract][Full Text] [Related]
5. Muscle involvement in myasthenia gravis: Expanding the clinical spectrum of Myasthenia-Myositis association from a large cohort of patients.
Garibaldi M; Fionda L; Vanoli F; Leonardi L; Loreti S; Bucci E; Di Pasquale A; Morino S; Vizzaccaro E; Merlonghi G; Ceccanti M; Lucchini M; Mirabella M; Andreetta F; Pennisi EM; Petrucci A; Salvetti M; Antonini G
Autoimmun Rev; 2020 Apr; 19(4):102498. PubMed ID: 32062029
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report.
Kamo H; Hatano T; Kanai K; Aoki N; Kamiyama D; Yokoyama K; Takanashi M; Yamashita Y; Shimo Y; Hattori N
BMC Neurol; 2019 Aug; 19(1):184. PubMed ID: 31382909
[TBL] [Abstract][Full Text] [Related]
7. A case report of nivolumab-induced myasthenia gravis and myositis in a metastatic renal cell carcinoma patient.
Nakanishi S; Nishida S; Miyazato M; Goya M; Saito S
Urol Case Rep; 2020 Mar; 29():101105. PubMed ID: 31908963
[TBL] [Abstract][Full Text] [Related]
8. Anti-Kv1.4 Antibody-positive Nivolumab-induced Myasthenia Gravis and Myositis Presenting with Bilateral Ptosis and Demonstrating Different Pathophysiologies.
Kitazaki Y; Yamamura O; Usui K; Ueno A; Sanada S; Sasaki H; Endo Y; Enomoto S; Ikawa M; Nakamoto Y; Hamano T
Intern Med; 2023; 62(20):3013-3020. PubMed ID: 37839874
[TBL] [Abstract][Full Text] [Related]
9. Exploring the role of immune checkpoint inhibitors in the etiology of myasthenia gravis and Lambert-Eaton myasthenic syndrome: A systematic review.
Seligman C; Chang YM; Luo J; Garden OA
Front Neurol; 2022; 13():1004810. PubMed ID: 36698907
[TBL] [Abstract][Full Text] [Related]
10. Myasthenia gravis induced or exacerbated by immune checkpoint inhibitors: a rising concern.
Hajihossainlou B; Vasileva A; Manthri S; Chakraborty K
BMJ Case Rep; 2021 Aug; 14(8):. PubMed ID: 34426425
[TBL] [Abstract][Full Text] [Related]
11. Immunopathology of Autoimmune Myasthenia Gravis: Implications for Improved Testing Algorithms and Treatment Strategies.
Frykman H; Kumar P; Oger J
Front Neurol; 2020; 11():596621. PubMed ID: 33362698
[TBL] [Abstract][Full Text] [Related]
12. Necrotizing myositis in a rectus muscle arising in the setting of long-standing Langerhans cell histiocystosis and recent dabrafenib treatment.
van Landingham SW; Puccetti D; Potter H; Gamm D; Diamond EL; Lucarelli MJ
Am J Ophthalmol Case Rep; 2020 Dec; 20():100868. PubMed ID: 32875153
[TBL] [Abstract][Full Text] [Related]
13. [A case of anti-titin antibody positive nivolumab-related necrotizing myopathy with myasthenia gravis].
Isami A; Uchiyama A; Shimaoka Y; Suzuki S; Kawachi I; Fujita N
Rinsho Shinkeigaku; 2019 Jul; 59(7):431-435. PubMed ID: 31243249
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab-induced Ocular Myasthenia Gravis with Anti-titin Antibody and Necrotizing Myopathy.
Onda A; Miyagawa S; Takahashi N; Gochi M; Takagi M; Nishino I; Suzuki S; Oishi C; Yaguchi H
Intern Med; 2019 Jun; 58(11):1635-1638. PubMed ID: 30713313
[TBL] [Abstract][Full Text] [Related]
15. Myasthenia gravis and myopathy after nivolumab treatment for non-small cell lung carcinoma: A case report.
Kim JS; Nam TS; Kim J; Kho BG; Park CK; Oh IJ; Kim YC
Thorac Cancer; 2019 Oct; 10(10):2045-2049. PubMed ID: 31436031
[TBL] [Abstract][Full Text] [Related]
16. [A case of myasthenia gravis and myositis induced by pembrolizumab].
Noda T; Kageyama H; Miura M; Tamura T; Ito H
Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management.
Kang KH; Grubb W; Sawlani K; Gibson MK; Hoimes CJ; Rogers LR; Lavertu P; Yao M
Am J Otolaryngol; 2018; 39(5):642-645. PubMed ID: 29903623
[TBL] [Abstract][Full Text] [Related]
18. Myositis and myasthenia during nivolumab administration for advanced lung cancer: a case report and review of the literature.
Veccia A; Kinspergher S; Grego E; Peterlana D; Berti A; Tranquillini E; Caffo O
Anticancer Drugs; 2020 Jun; 31(5):540-544. PubMed ID: 32011360
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
